Inhibikase Therapeutics News

Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress

TipRanksApr 2 15:15 ET

Inhibikase Therapeutics Analyst Ratings

BenzingaMar 7 11:24 ET

Inhibikase Therapeutics Analyst Ratings

BenzingaMar 5 10:49 ET

Inhibikase Therapeutics: Buy Rating Affirmed Amid Promising Drug Candidates and Strong Financial Standing

TipRanksFeb 21 08:36 ET

Promising Developments and Financial Outlook for Inhibikase Therapeutics Prompt Buy Rating

TipRanksOct 4, 2023 10:15 ET

Inhibikase Therapeutics (IKT) Gets a Hold From JonesTrading

TipRanksAug 18, 2023 16:25 ET

Inhibikase Therapeutics Analyst Ratings

BenzingaAug 15, 2023 11:50 ET

H.C. Wainwright Remains a Buy on Inhibikase Therapeutics (IKT)

TipRanksAug 15, 2023 10:35 ET

H.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

TipRanksJun 30, 2023 10:05 ET

Inhibikase Therapeutics (IKT) Receives a Buy From H.C. Wainwright

TipRanksJun 22, 2023 10:25 ET

H.C. Wainwright Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)

TipRanksMay 16, 2023 10:55 ET

JonesTrading Reaffirms Their Hold Rating on Inhibikase Therapeutics (IKT)

TipRanksApr 28, 2023 16:12 ET

Analysts Offer Insights on Healthcare Companies: Inhibikase Therapeutics (IKT) and Blue Water Vaccines, Inc. (BWV)

TipRanksApr 26, 2023 10:14 ET

HC Wainwright & Co. Initiates Coverage On Inhibikase Therapeutics With Buy Rating, Announces Price Target of $5

BenzingaApr 18, 2023 06:18 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and Inhibikase Therapeutics (IKT)

TipRanksDec 8, 2022 13:05 ET

Inhibikase Therapeutics Analyst Ratings

Benzinga Analyst RatingsNov 16, 2022 08:12 ET

Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), CASI Pharmaceuticals (CASI) and Inhibikase Therapeutics (IKT)

TipRanksAug 15, 2022 11:10 ET